AR113908A1 - Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson - Google Patents

Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson

Info

Publication number
AR113908A1
AR113908A1 ARP180103436A ARP180103436A AR113908A1 AR 113908 A1 AR113908 A1 AR 113908A1 AR P180103436 A ARP180103436 A AR P180103436A AR P180103436 A ARP180103436 A AR P180103436A AR 113908 A1 AR113908 A1 AR 113908A1
Authority
AR
Argentina
Prior art keywords
formula
substituent
compounds
disease
treatment
Prior art date
Application number
ARP180103436A
Other languages
English (en)
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of AR113908A1 publication Critical patent/AR113908A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente proporciona compuestos de fórmula (1), que son profármacos de catecolamina para uso en el tratamiento de enfermedades y trastornos neurodegenerativos. La presente proporciona también composiciones farmacéuticas que comprenden compuestos de la misma y métodos de tratar enfermedades y trastornos neurodegenerativos o neuropsiquiátricos utilizando los compuestos de la presente, en particular la enfermedad de Parkinson. Por consiguiente, la presente se refiere a compuestos de fórmula (2) donde R¹ es H y R² se selecciona de uno de los sustituyentes de fórmula (3) y (4) que figuran más adelante; o R¹ se selecciona de uno de los sustituyentes de fórmula (3) y (4) que figuran más adelante y R² es H; o R¹ y R² se representan ambos por el sustituyente de fórmula (3) que figura más adelante; o R¹ y R² se representan ambos por el sustituyente de fórmula (4) que figura más adelante; o R¹ es sustituyente de fórmula (3) y R² es sustituyente de fórmula (4); o R¹ es sustituyente de fórmula (4) y R² es sustituyente de fórmula (3); donde * indica el punto de unión; y donde el átomo de carbono en el punto de unión en el sustituyente de fórmula (3) está en la configuración S; o una sal farmacéuticamente aceptable del mismo.
ARP180103436A 2017-11-24 2018-11-23 Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson AR113908A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201700674 2017-11-24

Publications (1)

Publication Number Publication Date
AR113908A1 true AR113908A1 (es) 2020-06-24

Family

ID=64661284

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103436A AR113908A1 (es) 2017-11-24 2018-11-23 Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson

Country Status (25)

Country Link
US (4) US10729710B2 (es)
EP (1) EP3713933A1 (es)
JP (4) JP7320507B2 (es)
KR (1) KR20200092955A (es)
CN (3) CN117653649A (es)
AR (1) AR113908A1 (es)
AU (2) AU2018371193B2 (es)
BR (1) BR112019014981A2 (es)
CA (1) CA3082757A1 (es)
CL (1) CL2020001343A1 (es)
CO (1) CO2020006224A2 (es)
CR (1) CR20200225A (es)
EA (1) EA202090987A8 (es)
EC (1) ECSP20030074A (es)
GE (1) GEP20227446B (es)
IL (1) IL274648B1 (es)
JO (1) JOP20200114A1 (es)
MA (1) MA50800A (es)
MX (2) MX2020005366A (es)
PE (1) PE20211290A1 (es)
PH (1) PH12020550631A1 (es)
SG (1) SG11202004461YA (es)
TW (1) TWI816716B (es)
UA (1) UA127575C2 (es)
WO (1) WO2019101917A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50800A (fr) * 2017-11-24 2020-09-30 H Lundbeck As Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
US11104697B2 (en) * 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP7514859B2 (ja) 2019-05-21 2024-07-11 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
EP3972959A1 (en) * 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP2022533913A (ja) * 2019-05-21 2022-07-27 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP2023552699A (ja) 2020-11-17 2023-12-19 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2023208869A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
WO2023208865A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
ATE56958T1 (de) 1981-10-16 1990-10-15 Sandoz Ag 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)chinolinderivate mit pharmazeutischer wirkung.
FR2540112B1 (fr) 1983-02-01 1986-08-29 Sandoz Sa Nouveaux derives de la benzo(g)quinoleine, leur preparation et leur utilisation comme medicaments
JPS60172975A (ja) 1984-02-15 1985-09-06 Sumitomo Chem Co Ltd エリスロ−３−（３，４−メチレンジオキシフエニル）セリンの製造方法
GB2192394A (en) 1986-07-11 1988-01-13 Glaxo Group Ltd Amine derivatives
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
ATE118216T1 (de) 1989-04-20 1995-02-15 Zambon Spa Dopamin-medikament-vorstufe.
WO1990012574A1 (en) 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
IT1271411B (it) 1993-09-14 1997-05-28 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
US5955468A (en) 1993-12-21 1999-09-21 Sandoz Ltd. Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
IT1289979B1 (it) 1997-02-26 1998-10-19 Zambon Spa 5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
GB9902938D0 (en) 1999-02-10 1999-03-31 Novartis Ag Organic compounds
CO5261532A1 (es) 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
CZ20023637A3 (cs) 2000-04-07 2003-02-12 Tap Pharmaceutical Products, Inc. Deriváty apomorfinu a způsoby jejich použití
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
KR20030027020A (ko) 2000-08-11 2003-04-03 펄듀 리서치 파운데이션 디나프솔린의 제조 공정
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
PE20030240A1 (es) 2001-07-09 2003-04-16 Novartis Ag DERIVADOS DE BENZO [g] QUINOLINA
EP1414457B1 (en) 2001-08-10 2007-06-20 Purdue Research Foundation Chiral dinapsoline
EG24415A (en) 2002-03-07 2009-05-25 Novartis Ag Quinoline derivatives
KR20050008658A (ko) 2002-03-19 2005-01-21 마이클 홀릭 아포모르핀의 글리코시드 및 오르토에스테르 글리코시드유도체들, 유사체들 및 그것의 용도
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
CN1964713A (zh) 2003-12-23 2007-05-16 达法尔摩公司 多巴胺－受体结合化合物的共同使用
WO2006012640A2 (en) 2004-07-21 2006-02-02 Darpharma, Inc. Method of administration of dopamine receptor agonists
WO2006056604A1 (en) 2004-11-25 2006-06-01 Evolva Ag Levodopa glycosyl derivatives, methods of preparation and use
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US20090124651A1 (en) 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
TW201035054A (en) 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
EP2557079A1 (en) 2011-08-09 2013-02-13 Nestec S.A. Synthesis of catechin and epicatechin conjugates
DE102011112496A1 (de) 2011-09-07 2013-03-07 Thanares GmbH 4-Methylcatecholderivate und deren Verwendung
CN102746351B (zh) 2012-07-23 2018-03-02 上海弈柯莱生物医药科技有限公司 灯盏花乙素及其类似物的制备方法
GB201319768D0 (en) 2013-11-08 2013-12-25 Glycosynth Ltd Naphthalene derived chromogenic enzyme substrates
EP3569587A1 (en) 2014-10-21 2019-11-20 AbbVie Inc. Intermediates and process for preparing l-dopa diphosphate
CN105218606B (zh) 2015-10-19 2017-12-01 昆明理工大学 一种制备灯盏乙素的方法
EP4295909A3 (en) 2016-04-20 2024-07-17 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
US9920342B2 (en) 2016-05-17 2018-03-20 Divi's Laboratories Limited Process for the preparation of Droxidopa
MA50800A (fr) 2017-11-24 2020-09-30 H Lundbeck As Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP2022533913A (ja) 2019-05-21 2022-07-27 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP7514859B2 (ja) 2019-05-21 2024-07-11 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
EP3972959A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
EP3972600A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
JP2023013012A (ja) * 2021-07-15 2023-01-26 株式会社日立製作所 運行提案システム、及び運行提案作成方法

Also Published As

Publication number Publication date
CA3082757A1 (en) 2019-05-31
MX2020005366A (es) 2020-08-13
PE20211290A1 (es) 2021-07-20
PH12020550631A1 (en) 2021-02-22
MA50800A (fr) 2020-09-30
CO2020006224A2 (es) 2020-05-29
SG11202004461YA (en) 2020-06-29
RU2020116419A (ru) 2021-12-27
US20220257623A1 (en) 2022-08-18
TWI816716B (zh) 2023-10-01
AU2018371193A1 (en) 2020-06-11
US11110110B2 (en) 2021-09-07
JP2023145579A (ja) 2023-10-11
CN111386267A (zh) 2020-07-07
US20190160083A1 (en) 2019-05-30
US10729710B2 (en) 2020-08-04
US20200338102A1 (en) 2020-10-29
CR20200225A (es) 2020-07-25
EA202090987A1 (ru) 2020-08-07
US20240156851A1 (en) 2024-05-16
JOP20200114A1 (ar) 2020-05-17
US11707476B2 (en) 2023-07-25
CN117653649A (zh) 2024-03-08
CN117599073A (zh) 2024-02-27
TW201924693A (zh) 2019-07-01
AU2018371193B2 (en) 2022-12-22
JP2021504345A (ja) 2021-02-15
IL274648B1 (en) 2024-06-01
WO2019101917A1 (en) 2019-05-31
KR20200092955A (ko) 2020-08-04
ECSP20030074A (es) 2020-07-31
UA127575C2 (uk) 2023-10-18
JP2023145580A (ja) 2023-10-11
EA202090987A8 (ru) 2020-09-29
GEP20227446B (en) 2022-12-12
AU2023201741A1 (en) 2023-04-20
EP3713933A1 (en) 2020-09-30
JP7320507B2 (ja) 2023-08-03
CL2020001343A1 (es) 2020-09-25
BR112019014981A2 (pt) 2020-04-07
JP7320684B2 (ja) 2023-08-03
IL274648A (en) 2020-06-30
JP2023055830A (ja) 2023-04-18
CN111386267B (zh) 2023-12-12
MX2022016276A (es) 2023-02-09
JP7443606B2 (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
AR113908A1 (es) Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
DOP2020000037A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
AR101177A1 (es) Inhibidores de la syk
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
MX2016017147A (es) Compuestos de indazole substituidos como inhibidores de irak4.
CR20160287A (es) Inhibidores de syk
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
BR112015013414A2 (pt) derivados de naftiridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
EA202190359A1 (ru) Способы лечения нейродегенеративных расстройств
AR120158A2 (es) Derivados de indol mono o di sustituidos como inhibidores de la replicación viral del dengue
AR111416A2 (es) Compuesto terapéutico para el dolor y síntesis del compuesto
PH12019502792A1 (en) Tetrahydropyridopyrazine modulators of gpr6
EA201892640A1 (ru) Лечение болезни паркинсона